What Is the House of Commons Library Briefing on Medical Cannabis?

```html

The House of Commons Library briefing on medical cannabis, officially catalogued as CBP-8355, represents one of the most authoritative public-policy resources available on the medical use of cannabis within the United Kingdom. It is part of a suite of detailed Parliament research briefings designed to inform MPs, peers, and the general public about the complex legislative and medical science landscape surrounding cannabis. Understanding the briefing is essential not only for those following cannabis reform but also for healthcare professionals, patients, and companies involved in the pharmaceutical sector, such as Nationwide Pharmacies, one of the UK’s licensed cannabis pharmacies.

What is the House of Commons Library Briefing CBP-8355?

The House of Commons Library is the research wing of the UK Parliament. It produces impartial, detailed briefings on specific topics to aid parliamentary scrutiny and public understanding. The briefing papers are publicly accessible and regularly updated. The briefing titled CBP-8355, focusing on medical cannabis, particularly aims to:

Clarify the legislative status of cannabis in the UK
Explain the changes to medical cannabis law that occurred in November 2018
Outline the practical barriers to NHS access and prescribing
Address common confusions between legal classifications such as “Class” and “Schedule”

In legal and medical policy discussions, this briefing is often the go-to primer because it simultaneously explains law and policy in plain language while connecting quick references to original legislation and authoritative government sources.

Class vs Schedule: Clearing Up a Common Confusion

A frequent source of confusion is between the terms “Class” and “Schedule” when referring to cannabis under UK law. They are related but distinct legal concepts that play different roles in the control of drugs.

What is a Class?

The Misuse of Drugs Act 1971 (MDA) classifies controlled substances into Classes A, B, and C based on their perceived harm, with Class A being the most harmful. Cannabis is currently a Class B drug under this Act, making it illegal to possess, supply, or produce without a licence, except for specific medical exemptions.

What is a Schedule?

Separately, the Misuse of Drugs Regulations 2001 set out Schedules 1 to 5, which regulate how controlled drugs can be prescribed, manufactured, and distributed. Scheduling deals with the legal medical use rather than simply criminalising the drug. For example, cannabis-derived medicinal products are listed mostly in Schedules 2 and 4, allowing tntmagazine them—but only under strict regulatory conditions—to be prescribed by healthcare professionals.

Why does this distinction matter?

Class
Schedule

Misunderstandings occur when people say “cannabis is legalised” because it is available on prescription. In reality, cannabis remains illegal as a Class B drug but can be prescribed as a Schedule 2 or 4 medicine under tight controls.

Takeaway: Class relates to criminal law; Schedule relates to medical regulation.

What Changed in November 2018?

The biggest recent legislative shift covered by the briefing was the rescheduling of cannabis-derived medicinal products in November 2018. Prior to this, despite calls for reform, cannabis-based medicines were effectively unavailable on the NHS except through private prescriptions, often at significant cost.

Following high-profile cases and public pressure, the Home Office announced that cannabis-based products for medicinal use would be reclassified as Schedule 2 drugs. This change meant:

Specialist doctors could legally prescribe cannabis medicines via the NHS for select conditions.
Patients gained a legal route to obtain cannabis-based medicines rather than relying solely on unlicensed or private alternatives.
The UK government recognised the medicinal potential of cannabis, albeit with cautious restrictions remaining in place.

However, the rescheduling did not change cannabis’s status as a Class B drug under the 1971 Act, which means recreational use remains illegal and possession without licence is still a criminal offence.

Since November 2018, cannabis-based medicines can be prescribed for severe epilepsy, nausea related to chemotherapy, and muscle spasticity in multiple sclerosis but only by specialist consultants.

Takeaway: November 2018 rescheduling permitted specialist prescribing but did not legalise cannabis recreationally.

Why Does Cannabis Remain Illegal Under the 1971 Act?

The 1971 Misuse of Drugs Act remains the foundational law controlling drugs in the UK. Despite the medical reforms, the UK government has explicitly chosen not to legalise or decriminalise cannabis recreationally. Several reasons underlie this:

Public health concerns: The government cites potential harms to mental health and youth.
Lack of conclusive broad medical evidence: Although some evidence supports medical use, comprehensive long-term studies are still limited.
International obligations: UK drug-control treaties also regulate cannabis as a controlled substance.
Political considerations: The topic remains contested, with ministers balancing public opinion, medical interests, and law enforcement.

As a result, cannabis remains Class B for recreational use, with strict penalties for possession, cultivation, and supply except for authorised medical products and licences.

Takeaway: Medical reform coexists with continued prohibition of recreational cannabis under the 1971 Act.

Specialist-Only Prescribing and Why NHS Access Is Limited

A critical feature highlighted in the House of Commons Library briefing is that, unlike many other medicines, cannabis-based products can only be prescribed on the NHS by specialists—not general practitioners (GPs). The rationale includes:

Complexity and risk: Specialist oversight ensures patient safety with careful selection and monitoring.
Limited evidence base: Specialists can interpret and balance emerging evidence for particular clinical indications.
NHS caution: The National Health Service has been slow to adopt prescribing due to cost-effectiveness concerns and funding pressures.

Because of these restrictions, many patients who might benefit from medical cannabis find it difficult to get NHS prescriptions. Consequently, some turn to private prescriptions or licensed specialist pharmacies such as Nationwide Pharmacies. These pharmacies manage the supply chain for medicinal cannabis products with appropriate regulatory licences, providing access where NHS routes are unavailable or impractical.

Despite this, the high cost of private prescriptions means NHS patients face inequity of access based on geography, condition, and financial means.

Takeaway: NHS prescribing is tightly controlled, limiting access to medical cannabis despite legal reform.

Conclusion: Understanding the Briefing Is Key to Navigating Medical Cannabis Policy

The House of Commons Library briefing CBP-8355 remains an essential resource for anyone seeking to understand the evolving legal, medical, and policy frameworks surrounding medical cannabis in the UK. By clarifying the difference between Class and Schedule, summarising the November 2018 reforms, and explaining why cannabis remains illegal outside medical use, the briefing dispels many myths and misstatements in public debate.

For patients and clinicians, the briefing underscores why specialist-only prescribing and cautious NHS adoption continue to shape the reality on the ground. Meanwhile, companies like Nationwide Pharmacies are key players in delivering licensed medical cannabis, navigating the complex framework described in the briefing.

Precise language matters: cannabis in the UK is not “legalised” but carefully regulated for medical use under strict licences. The House of Commons Library briefing provides the clear, fact-checked context needed to engage responsibly with this fast-moving area of law and medicine.

```